Tag: Webcast

In this session Felix Gold Executive Director Joseph Webb discussed how Felix’ strategic location could set them up for a near-term, low-cost development pathway including a deal with an ore-hungry mill next door.

In this session Far East Gold’s CEO and Director Shane Menere discussed the standout assays from our Woyla drilling campaigns that form the base of our upcoming maiden JORC resource publication.

In this session Prescient CEO and Managing Director Steven Yatomi-Clarke discussed why the data from their PTX-100 Phase 1b trial is so promising.

In this session Felix Gold Executive Director Joseph Webb discussed how their strategic location and exploration efforts have put the company on the cusp of near-term value creation, against a backdrop of record gold prices

In this session Prescient CEO and Managing Director Steven Yatomi-Clarke provide a company update on strategy and upcoming milestones.

Join Stuart Roberts, co-founder and senior analyst at Pitt Street Research, for an online briefing where he will outline the recent Pitt Street Research report on Prescient Therapeutics.

In this session Far East Gold’s CEO and Director Shane Menere discussed, why the Board (including Nickel Industries MD Justin Werner) is optimistic about the findings so far……

In this session Wellnex Life MD Zack Bozinovski and Non-Executive Chairman Mario Tascone discussed what attracted Mario to Wellnex and where he sees the future of the business;

In this session VP Minerals (VPM) Non-Executive Director Graham Howard discussed VPM’s continued resource inventory targeting high grade critical mineral deposits.

In this session Propell CEO Michael Davidson discussed Propell’s recent progress on the platform, cost base, and establishing a broker network…

In this session International Operations Director of Site Group, Vernon Wills discussed Site’s recent contract wins, growth opportunities and the key catalysts ahead.

In this session Prescient CEO and Managing Director Steven Yatomi-Clarke discussed the new PTX-100 Phase 1b clinical study results, following their unveiling at the American Society of Hematology (ASH) conference.